venetoclax
roche,abbvie
['venetoclax']
2/6 phase ii study of mini-hyper-cvd plus venetoclax in patients with ph-neg all pts &gt;18y with r/r b/t-all. n=20 (b-15, t-5)
evaluable=19; mfu=15 mos. orr=12/19 (63%)[9cr,3 cri; mrd-ve=6/12]. 9/12 resp after c1 
Leukemia fellow at MD Anderson.
(CMC Vellore and AIIMS New Delhi alumnus).Opinionated and adore rationality!Tweets are my own. Science for humanity? 
??????????